Trials / Completed
CompletedNCT00967018
A Long Term Safety Study of Degarelix in Patients With Prostate Cancer
A Phase IIIb, Non-randomized, Open-label, Multi-Centre, Follow-on Safety Trial of Monthly Doses of Degarelix in Patients With Prostate Cancer
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 77 (actual)
- Sponsor
- Ferring Pharmaceuticals · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Patients that completed any of the trials; CS27 (NCT00738673), CS28 (NCT00831233), CS30 (NCT00833248) or CS31 (NCT00884273) will be given the opportunity to receive monthly doses of degarelix until the drug is launched in their country. Safety parameters such as electrocardiogram (ECG), blood and urine samples and general health state will be studied. Note: patients completing the CS27 trial did not participate in the CS34 trial.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Degarelix |
Timeline
- Start date
- 2009-08-01
- Primary completion
- 2011-11-01
- Completion
- 2011-12-01
- First posted
- 2009-08-27
- Last updated
- 2013-01-03
- Results posted
- 2012-12-24
Locations
62 sites across 7 countries: Belgium, France, Italy, Portugal, Spain, Sweden, Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT00967018. Inclusion in this directory is not an endorsement.